AFM - Fluorometholone Acetate | VetSafeCare.Com

Brand

AFM

Fluorometholone Acetate — Aristopharma Ltd.
0.1% / ophthalmic suspension

Alternatives

16

Routes

OPH

Presentations

1

Generic profile Browse alternatives View combinations

Presentations

Ophthalmic Suspension · 0.1% / ophthalmic suspension

5 ml

৳100

Dose rules

No structured dose rules are linked to this brand yet.

Dose reference

Human

1 drop instilled into the conjunctival sac 2-4 times daily. During the initial 24 to 48 hours the dosage may be safely increased to 1 drop every hour. Care should be taken not to discontinue therapy prematurely. Shake well before use.

Clinical notes

Applications:

N/A

Indication Notes:
Fluorometholone Acetate ophthalmic suspension is indicated for the treatment of- Acute and chronic non-infectious conjunctivitis and keratitis of allergic origin. Non-infectious inflammation of the anterior chamber of the eye (including anterior uveitis, episcleritis and scleritis). ... Read moreFluorometholone Acetate ophthalmic suspension is indicated for the treatment of- Acute and chronic non-infectious conjunctivitis and keratitis of allergic origin. Non-infectious inflammation of the anterior chamber of the eye (including anterior uveitis, episcleritis and scleritis). Post-operative irritative conditions after strabismus, cataract and glaucoma surgery.
Avoid In:

N/A

Contraindication Notes:
Hypersensitivity to any ingredient of the formulation. Infectious conjunctivitis or keratitis. Injuries and ulcerous processes of cornea, especially infections caused by virus, bacteria and fungi. Dry eyes, especially keratoconjunctivitis sicca. Glaucoma.
Fluorometholone is a corticosteroid with an excellent anti-inflammatory action with no significant influence on the intraocular pressure. The anti-inflammatory activity of Fluorometholone is at least 40 times stronger than that of Hydrocortisone. Corticosteroids are thought to act by the introduction of phospholipase A2 inhibitory proteins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandin and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. In comparison with other corticosteroids Fluorometholone is more rapidly degraded in tissue and therefore has less effect on the intraocular pressure. The immunosuppressive action of Fluorometholone is less pronounced than that of Dexamethasone.
Specific drug interaction studies have not been conducted with Fluorometholone ophthalmic suspension.
Glaucoma with optic nerve damage, visual acuity or field defects, cataract formation, secondary ocular infection following suppression of host immunity, perforation of the globe.
Safety of the use of topical steroids during pregnancy and lactation has not been established. Fluorometholone ophthalmic suspension should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Shake well before using. If this product is used for 10 days or longer, intraocular pressure should be monitored.